Tema Heart & Health ETF (NASDAQ:HRTS) Stock Short Interest Report for September

Tema Heart & Health ETF (NASDAQ:HRTS) saw a significant drop in short interest in September. As of September 30th, there was short interest totaling 520 shares, a drop of 43.3% from the September 15th total of 917 shares. Based on an average daily volume of 1,835 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the company’s stock are short sold.

Tema Heart & Health ETF Trading Down 0.9%

Shares of NASDAQ:HRTS traded down $0.32 during mid-day trading on Friday, hitting $36.91. 2,360 shares of the company traded hands, compared to its average volume of 5,306. The stock has a 50-day moving average price of $36.96 and a two-hundred day moving average price of $35.57. Tema Heart & Health ETF has a 12-month low of $31.95 and a 12-month high of $38.87. The stock has a market cap of $54.62 million, a P/E ratio of 22.06 and a beta of 0.65.

Hedge Funds Weigh In On Tema Heart & Health ETF

Several large investors have recently bought and sold shares of the stock. XML Financial LLC purchased a new stake in shares of Tema Heart & Health ETF in the second quarter valued at about $223,000. Anson Capital Inc. bought a new position in shares of Tema Heart & Health ETF during the second quarter valued at about $297,000. Members Advisory Group LLC purchased a new position in Tema Heart & Health ETF during the second quarter worth about $398,000. Royal Bank of Canada boosted its holdings in Tema Heart & Health ETF by 8.8% during the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after purchasing an additional 1,703 shares during the last quarter. Finally, Rothschild Capital Partners LLC purchased a new position in Tema Heart & Health ETF during the second quarter worth about $651,000.

About Tema Heart & Health ETF

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.